Daclatasvir: potential role in hepatitis C [Corrigendum]
Lee C. Drug Des Devel Ther. 2013;7:1223–1233. On page 1231 in the "Conclusion" section, line 3 contains incorrect information. The correct sentence is "This review summarizes key preclinical and clinical data of an HCV NS5A inhibitor, DCV, describing its discover...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2014-03-01
|
| Series: | Drug Design, Development and Therapy |
| Online Access: | http://www.dovepress.com/daclatasvir-potential-role-in-corrigendum-peer-reviewed-article-DDDT |
| _version_ | 1818936411164770304 |
|---|---|
| author | Lee C |
| author_facet | Lee C |
| author_sort | Lee C |
| collection | DOAJ |
| description | Lee C. Drug Des Devel Ther. 2013;7:1223–1233. On page 1231 in the "Conclusion" section, line 3 contains incorrect information. The correct sentence is "This review summarizes key preclinical and clinical data of an HCV NS5A inhibitor, DCV, describing its discovery, mechanism of action, resistance profile, in vitro and in vivo efficacy and toxicity, and polymorphism."Read the original article |
| first_indexed | 2024-12-20T05:35:38Z |
| format | Article |
| id | doaj.art-49b48ba9dd174fcda26872ebaf96caee |
| institution | Directory Open Access Journal |
| issn | 1177-8881 |
| language | English |
| last_indexed | 2024-12-20T05:35:38Z |
| publishDate | 2014-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj.art-49b48ba9dd174fcda26872ebaf96caee2022-12-21T19:51:37ZengDove Medical PressDrug Design, Development and Therapy1177-88812014-03-012014default32532616154Daclatasvir: potential role in hepatitis C [Corrigendum]Lee CLee C. Drug Des Devel Ther. 2013;7:1223–1233. On page 1231 in the "Conclusion" section, line 3 contains incorrect information. The correct sentence is "This review summarizes key preclinical and clinical data of an HCV NS5A inhibitor, DCV, describing its discovery, mechanism of action, resistance profile, in vitro and in vivo efficacy and toxicity, and polymorphism."Read the original articlehttp://www.dovepress.com/daclatasvir-potential-role-in-corrigendum-peer-reviewed-article-DDDT |
| spellingShingle | Lee C Daclatasvir: potential role in hepatitis C [Corrigendum] Drug Design, Development and Therapy |
| title | Daclatasvir: potential role in hepatitis C [Corrigendum] |
| title_full | Daclatasvir: potential role in hepatitis C [Corrigendum] |
| title_fullStr | Daclatasvir: potential role in hepatitis C [Corrigendum] |
| title_full_unstemmed | Daclatasvir: potential role in hepatitis C [Corrigendum] |
| title_short | Daclatasvir: potential role in hepatitis C [Corrigendum] |
| title_sort | daclatasvir potential role in hepatitis c corrigendum |
| url | http://www.dovepress.com/daclatasvir-potential-role-in-corrigendum-peer-reviewed-article-DDDT |
| work_keys_str_mv | AT leec daclatasvirpotentialroleinhepatitisccorrigendum |